ClinicalTrials.gg
TerminatedNCT01676935Updated Aug 2, 2021

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

A Phase 2 interventional study of ABT-126 in Alzheimer's Disease, sponsored by AbbVie (prior sponsor, Abbott). Terminated at 29 sites in 6 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-08-02.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
349
Allocation
Not applicable
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Alzheimer Disease by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · AbbVie.

Enrollment
7th of 27
349 · median 210
Started
2012
with 3 others
Phase 2
14 of 27
none open now
Registered
11th of 27
by date

Among the 27 studies in Alzheimer Disease by AbbVie, this one is the 7th largest by enrollment, is one of 4 that started in 2012, is one of 14 in phase 2, and was the 11th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 27 studies in Alzheimer Disease by AbbVie is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease by AbbVie, or all of them as a file.
02

Study summary

This is a long term extension study to evaluate safety and tolerability of subjects who complete study M10-985 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Read the detailed description

This is a Phase 2, open-label, multicenter, 28 week extension study to evaluate the long-term safety and tolerability of ABT-126 in subjects who complete dosing through Week 24 of Study M10-985. Up to 410 subjects may participate at approximately 30 sites in several countries.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject and caregiver must voluntarily sign and date an . If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject. - The subject was randomized into Study M10-985 and completed dosing through Week 24 in that study. - With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead . - If male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of (condom) with spermicidal foam/gel/film/cream/suppository for the duration of the study and for 30 days following the last dose of study drug. However, if the male subject's partner has been for at least 2 years or is surgically sterile, then use of a barrier method of birth control is not required. - The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study. - The subject and caregiver must have sufficient visual, hearing and graphomotor skills to complete the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Experienced an adverse event or abnormal finding in physical examination, vital signs, laboratory profile and/or measurements in Study M10-985 that indicates the subject could become medically unstable during the current study. - The subject is currently taking or is expected to be prescribed any excluded medications (including acetylcholinesterase inhibitors or memantine), without the approval of Abbott medical monitor. - The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals. - The subject is currently enrolled in, or plans to participate in, another experimental study during the course of this trial. - The subject developed any significant medical or psychiatric condition that, in the opinion of the investigator, renders the subject an unsuitable candidate to participate in this study. - For any other reason the investigator considers the subject to be an unsuitable candidate to receive ABT-126 or to participate in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
349 participants (actual)

Study arms

  • Experimental
    ABT-126

    ABT-126 Open-label dose

    Drug: ABT-126

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Monitor each subject for clinical and laboratory evidence of adverse events on a routine basis throughout the study

    Time frame: Assessments up through 28 weeks

  2. Laboratory Data

    Assessments include hematology, clinical chemistry, urinalysis and urine drug/alcohol screens.

    Time frame: Assessments up through 28 weeks

  3. Vital Signs

    Assessments include pulse, blood pressure and oral body temperature

    Time frame: Assessments up through 28 weeks

  4. Physical examinations

    An examination of bodily functions and physical condition

    Time frame: Assessments up through 28 weeks

  5. Brief Neurological examination

    Assessments include cranial nerves, motor and sensory system, reflexes, coordination, gait and station

    Time frame: Assessments up through 28 weeks

  6. Brief Psychiatric assessments

    Assessments include mood, anxiety, psychosis or delusions, agitation, homicidal thoughts or behaviors.

    Time frame: Assessments up through 28 weeks

  7. Columbia-Suicide Severity Rating Scale

    The scale is designed to assess suicidal behavior and ideation

    Time frame: Assessments up through 28 weeks

  8. Cornell Scale for Depression in Dementia

    Assesses the signs and symptoms of major depression in patients with dementia.

    Time frame: Assessments up through 28 weeks

  9. Electrocardiogram

    Measurements include heart rate, RR interval, PR interval, QRS duration and QT intervals

    Time frame: Assessments up through 28 weeks

07

Study locations

29 sites
  • Site Reference ID/Investigator# 73493
    Delray Beach, Florida 33445, United States
  • Site Reference ID/Investigator# 73496
    West Palm Beach, Florida 33407, United States
  • Site Reference ID/Investigator# 73495
    Elk Grove Village, Illinois 60007, United States
  • Site Reference ID/Investigator# 73494
    Staten Island, New York 10312, United States
  • Site Reference ID/Investigator# 97035
    Wichita Falls, Texas 76309, United States
  • Site Reference ID/Investigator# 73514
    Poznan, 61-853, Poland
  • Site Reference ID/Investigator# 73515
    Szczecin, 71-215, Poland
  • Site Reference ID/Investigator# 73516
    Kazan, 420012, Russian Federation
  • Site Reference ID/Investigator# 73525
    Kazan, 420097, Russian Federation
  • Site Reference ID/Investigator# 73523
    Kirov, 610014, Russian Federation
  • Site Reference ID/Investigator# 73521
    Moscow, 119048, Russian Federation
  • Site Reference ID/Investigator# 73519
    Moscow, 123995, Russian Federation
  • Site Reference ID/Investigator# 73517
    Novosibirsk, 630064, Russian Federation
  • Site Reference ID/Investigator# 73520
    Saratov, 410060, Russian Federation
  • Site Reference ID/Investigator# 73518
    St. Petersburg, 190020, Russian Federation
  • Site Reference ID/Investigator# 73524
    St. Petersburg, 190103, Russian Federation
  • Site Reference ID/Investigator# 84615
    St. Petersburg, 192019, Russian Federation
  • Site Reference ID/Investigator# 73522
    St. Petersburg, 198510, Russian Federation
  • Site Reference ID/Investigator# 73507
    Belville, 7530, South Africa
  • Site Reference ID/Investigator# 84614
    Cape Town, 7925, South Africa
  • Site Reference ID/Investigator# 73505
    George, 6529, South Africa
  • Site Reference ID/Investigator# 73506
    Johannesburg, 2196, South Africa
  • Site Reference ID/Investigator# 73533
    Donetsk, 83037, Ukraine
  • Site Reference ID/Investigator# 73534
    Kiev, 04112, Ukraine
  • Site Reference ID/Investigator# 73535
    Poltava, 36006, Ukraine
  • Site Reference ID/Investigator# 73502
    Bath, BA1 3NG, United Kingdom
  • Site Reference ID/Investigator# 73503
    Blackburn, BB2 3HH, United Kingdom
  • Site Reference ID/Investigator# 73501
    Glasgow, G20 0XA, United Kingdom
  • Site Reference ID/Investigator# 73504
    London, TW8 8DS, United Kingdom
08

References and documents

Publications

  • Gault LM, Lenz RA, Ritchie CW, Meier A, Othman AA, Tang Q, Berry S, Pritchett Y, Robieson WZ. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther. 2016 Oct 18;8(1):44. doi: 10.1186/s13195-016-0210-1. PubMed 27756421 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2012
First posted
Aug 31, 2012
Start
Aug 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Aug 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01676935
Responsible party
Sponsor
First posted
Aug 31, 2012
Start date
Aug 2012
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Aug 2, 2021

Study contacts

Laura Gault, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABT-126

Start the discussion